Owen Hughes Purchases Shares of C4 Therapeutics

Owen Hughes, an insider at C4 Therapeutics, Inc. (NasdaqGS: CCCC), bought 62,000 shares of the company on June 24, 2026. This purchase adds to a series of insider transactions, highlighting ongoing interest within the company's leadership.

Insider Buying and Selling at C4 Therapeutics, Inc.

Several insiders, including Steven Hoerter, Laura Bessen, Stephen Fawell, Owen Hughes, Donna Roy Grogan, and Kenneth Carl Anderson, made notable purchases on June 24, 2026. Each bought 62,000 shares, except Anderson, who acquired 1,070 shares at an average price of $2.11 on June 1, 2026. These transactions were not under planned trading programs, suggesting confidence in the company's future.

Other Institutional Activity in C4 Therapeutics

Morgan Stanley increased its holdings in C4 Therapeutics by 90,738 shares, resulting in 9,072,400 shares valued at approximately $23.9 million. RA Capital Management, L.P. maintained its position with 8 million shares worth about $21 million. Bain Capital Life Sciences Investors, LLC also held steady with 7,171,910 shares valued at $18.9 million. Lynx1 Capital Management LP trimmed its stake by 99,231 shares, holding 6,998,902 shares worth $18.4 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at around $10.2 million.

C4 Therapeutics, Inc. Stock Up 14.3%

Shares of NasdaqGS:CCCC traded near $4.40 on Saturday. C4 Therapeutics has a market cap of about $471 million and a beta of 2.93, indicating higher volatility. The stock is trading close to its 52-week high of $4.60, with a 52-week low of $1.40. Its 50-day moving average is $3.51, and the 200-day moving average is $2.70. The company maintains a strong liquidity position with a current ratio of 9.0 and a quick ratio of 8.8, alongside a debt-to-equity ratio of 24.95.

Recent Earnings

C4 Therapeutics reported revenue of $34.9 million, though it experienced a revenue decline of 15%. The company posted a net margin of -297.8% and a return on equity of -48.3%. It is not yet profitable, with a negative forward P/E ratio. The next earnings release is expected on August 6, 2026.

Analysts Set New Price Targets

On June 1, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $12. Barclays and Brookline Capital also maintained 'buy' ratings with targets of $7 and $30, respectively, earlier in the year. The stock has a consensus recommendation of 'strong buy' with an average target price of $13.33 from six analysts.

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc., based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company developing therapies to degrade disease-causing proteins. The company focuses on treatments for multiple myeloma and non-small cell lung cancer, with its lead product candidate, Cemsidomide, targeting IKZF1 and IKZF3 proteins. C4 Therapeutics collaborates with major pharmaceutical companies like Roche and Merck to advance its therapeutic pipeline.

Bottom Line

Owen Hughes's purchase of C4 Therapeutics shares underscores insider confidence in the company's future. The stock is trading close to its 52-week high, backed by a strong 'buy' consensus among analysts. Investors often track insider transactions for potential insights, though these trades are disclosed after the fact and may not reflect current conditions.